Sequential Skin announced it has received $1.65 million in oversubscribed seed round investments, led by Metaplanet, and supported by Scrum Ventures, SOSV, Genedant and angel investor, Ben Holmes.
The $1.65 million investment will allow the company to extend its B2B offerings to skin care, hair care and healthcare companies, with a focus on U.S. expansion.
The funding will also significantly boost its IP portfolio, using its patch-based, skin analysis, to develop further tools to understand how genetics, epigenetics and skin microbiome affect health.
Oliver Worsley, M.D., CEO and co-founder of Sequential Skin, says, “We now have significant traction in assembling an extensive dataset on skin types from Asia, Europe and the U.S.—a great chance for us to discover novel biomarkers for skin conditions in different populations.”
Rauno Miljand, managing partner at Metaplanet, says, “The world of skin care is flooded with a confusing array of products that only help some of the people, some of the time. We’re proud to lead the investment in Sequential Skin. It is the first company, using genomics and microbiome skin assays, that identifies to consumers the exact products suited for each individual. With Sequential Skin, users can get an insightful and deep understanding of their skin state and what is needed to satisfy the demands that their surrounding environment and lifestyle poses on their skin. We were impressed by the Sequential Skin team, and it seems one of the most promising personalized skincare companies currently on the market.”